US20200046767A1 - Method for generating t cells progenitors - Google Patents

Method for generating t cells progenitors Download PDF

Info

Publication number
US20200046767A1
US20200046767A1 US16/485,488 US201816485488A US2020046767A1 US 20200046767 A1 US20200046767 A1 US 20200046767A1 US 201816485488 A US201816485488 A US 201816485488A US 2020046767 A1 US2020046767 A1 US 2020046767A1
Authority
US
United States
Prior art keywords
cells
tnf
alpha
cell
vitro method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/485,488
Other languages
English (en)
Inventor
Isabelle André
Marina Cavazzana
Kuiying Ma
John Tchen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondation Imagine - Institut Des Maladies Genetiques
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Universite Paris Cite
Original Assignee
Fondation Imagine - Institut Des Maladies Genetiques
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondation Imagine - Institut Des Maladies Genetiques, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes filed Critical Fondation Imagine - Institut Des Maladies Genetiques
Assigned to INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ PARIS DESCARTES, FONDATION IMAGINE - INSTITUT DES MALADIES GÉNÉTIQUES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS reassignment INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAVAZZANA, MARINA, ANDRÉ, Isabelle, MA, Kuiying, TCHEN, John
Publication of US20200046767A1 publication Critical patent/US20200046767A1/en
Assigned to Université de Paris reassignment Université de Paris MERGER (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITE PARIS DESCARTES
Assigned to UNIVERSITÉ PARIS CITÉ reassignment UNIVERSITÉ PARIS CITÉ CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: Universite De Paris
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES, FONDATION IMAGINE - INSTITUT DES MALADIES GÉNÉTIQUES reassignment INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DEVI MOIRANGTHEM, RANJITA, SOHEILI, TAYEBEH-SHABI
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Definitions

  • the invention relates to the field of cell therapy, in particular of hematopoietic stem cells graft, transformed or not, and more particularly of immune reconstitution after such graft.
  • HSPC Hematopoietic Stem/Progenitor Cell
  • T lymphocyte differentiation pathway T cell progenitors
  • T cell precursors are obtained from CD34+ HSPC differentiation and have in particular the CD7+ marker, which is a marker of differentiation in the T-cell pathway. They may also have other markers.
  • CD7+ marker which is a marker of differentiation in the T-cell pathway. They may also have other markers.
  • Awong et al (Blood 2009; 114: 972-982) described the following precursors of T lymphocytes: early thymic progenitor (ETP), which have markers (CD34+/CD45RA+/CD7+), precursor cells at the proT1 stage (CD7++/CD5 ⁇ ), precursor cells at the proT2 stage (CD7++/CD5+), and cells at the preT stage (CD7++/CD5+ CD1a+).
  • ETP early thymic progenitor
  • the HSPC acquire these markers in a successive way when passing from one stage to the other, over the T cell development pathway.
  • CD1a antigen distinguishes the passage from a very immature thymic progenitor to a progenitor clearly engaged in the T-pathway (Cavazzana-Calvo et al, MEDECINE/SCIENCES 2006; 22: 151-9).
  • a T-cell precursors transplant, concomitant with HSPC grafting, would allow the rapid production of a mature and functional T lymphocyte compartment and thus help prevent the risk of severe infections by allowing the patient to benefit from some immunity before complete reconstitution of the immune system.
  • WO 2016/055396 describes that it is possible to generate T-cell precursors by culturing CD34+ cells in presence of an immobilized ligand of Notch (in particular the soluble domain of the Delta-like-ligand, fused to a Fc region of an IgG protein), and of a fragment of a fibronectin, containing the RGDS (SEQ ID NO: 3, Arginine-Glycine-Aspartate-Serine) and CS-1 domains, as well as the heparin-binding domain (in particular in the presence of Retronectin®).
  • the Notch ligand used may be referred to as DL4/Fc.
  • Notch proteins are transmembrane receptors that regulate the cellular response to a large number of environmental signals.
  • Notch 1-4 Notch 1-4 receptors
  • five ligands Delta-like-1, 3, and 4, Jagged1, Jagged2
  • the Delta-like-ligand 4 can be designated as:
  • Notch Delta-like-1 and Delta-like-4 ligands may be designated respectively by DL1 and DL4 or by DL-1 and DL-4.
  • the sequences of ligands DL-1 and DL-4 are specified as SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
  • Ohishi et al (BLOOD, vol. 98, no. 5, 2001, pp 1402-1407) relates to the effect of Notch signaling on monocyte differentiation into macrophages and dendritic cells.
  • the monocyte cells used in the experiments disclosed in this document were either peripheral blood monocytes purified by negative selection, or monocytes obtained after in vitro differentiation of CD34+ stem cells. The cells used in this document have thus entered the monocyte/macrophage/dendritic cells differentiation pathway, have lost the CD34 marker (which is a hematopoietic stem cell marker) and present the CD14 marker.
  • TNF-alpha which is used to induce the differentiation of CD34+ cell-derived CD1a-CD14+ cells into dendritic cells. This document this doesn't uses CD34+ cells in presence of a Notch ligand and of TNF-alpha and doesn't pertain to the generation of T-cell precursors (CD7+ T lymphocytes precursors).
  • SHUKLA et al (NATURE METHODS, vol. 14, no. 5, 2017, 531-538) and WO 2017/173551 disclose a method for generating progenitor T cells from stem and/or progenitor cells comprising exposing the stem and/or progenitor cells to Notch ligand Delta-like-4 (DL4) and vascular adhesion molecule 1 (VCAM-1).
  • DL4 Notch ligand Delta-like-4
  • VCAM-1 vascular adhesion molecule 1
  • the method described in the present application allows the generation and the increase (proliferation) of number of CD7+ T lymphocyte precursors, from CD34+ stem cells, without using a cell stroma (which can't be easily envisaged in a clinical context). Furthermore, the method is particularly adapted when performed with CD34+ cells issued from adult donors.
  • the cells obtained through the process as herein disclosed harbor the Bcl11b marker, which is important transcriptional factor uniquely switched on since T-cell commitment (Kueh et al, 2016, Nat Immunol. 2016 August; 17(8):956-65. doi: 10.1038/ni.3514).
  • the inventors have also shown absence of rearrangement of the T cell receptors loci (either TCRbeta, TCRgamma or TCRdelta) in the progenitors obtained through the process herein disclosed.
  • the process herein disclosed makes it possible to obtain a number of T cell precursors high enough to be efficiently used for an adult receiving a stem cells transplant.
  • This method may also be used to obtain transformed (transduced) T cell precursors for gene therapy, when a vector containing a gene of interest is used at some point during the process herein disclosed.
  • the cells obtained by the process herein disclosed can be obtained for adult CD34+ cells, and can be used for allogenic grafts or autografts, even when cord blood cells are used for such grafts.
  • the method herein disclosed thus fasten T-cell generation in vivo after injection of T-cell progenitors produced from HSPC in an in vitro culture system, combining an immobilized fusion protein derived from the Notch ligand, Delta-4, Retronectin® and a combination of cytokines.
  • T-cell progenitors that are phenotypically and molecularly similar to human thymic T-cell precursors. Furthermore, these T-cell progenitors are able to give rise human mature and diverse T-cell in NSG mice, with a faster kinetic as compared to HSPC.
  • T cell precursors can be improved from CD34+ cells by exposing said CD34+ cells to a Notch ligand and in the presence of the soluble TNF-alpha (Tumor Necrosis Factor Alpha, Uniprot P01375, RefSeq NP_000585, SEQ ID NO: 8). Said exposure is made under conditions suitable to generate progenitor T cells.
  • the cells are also exposed to a fibronectin fragment containing an RDGS motif, and/or a CS-1 motif and optionally a heparin binding domain.
  • said fibronectin fragment contains an RDGS motif, a CS-1 motif and a heparin binding domain.
  • TNF is primarily produced as a 233-amino acid-long type II transmembrane protein arranged in stable homotrimers.
  • the secreted form of human TNF-alpha takes on a triangular pyramid shape, and weighs around 17-kDa.
  • RGDS and/or CS-1 peptides may be present as such in the culture medium or within a polypeptide or protein present in the culture medium.
  • the culture medium only contains the RGDS and/or CS-1 peptide as such, one can relate to these as “free” peptide(s) in the culture medium if such peptides are not immobilized on the inner surface of the culture vessel.
  • the peptide(s) may be in solution or immobilized on the inner surface of the vessel in which the CD34+ cells are exposed to the immobilized Notch ligand.
  • fibronectin which contains the RGDS and CS-1 patterns, as well as a heparin-binding domain.
  • the fibronectin fragment may be free in solution or immobilized on the inner surface of the culture container.
  • the process is performed in vitro, in a container, such as a cell culture plate (Petri dish, 24 well array or the like), preferably with the Notch ligand immobilized on its inner surface.
  • the Notch ligand may, however, be immobilized on any other support present in the culture medium, such as on the surface of beads (in particular microbeads). Immobilization of the Notch ligand is essentially intended to stabilize the ligand, in order to allow activation of the Notch receptor of the CD34+ cells.
  • T cell progenitor By “T cell progenitor”, one intends to designate any cell involved in the differentiation pathway to the T lymphoid pathway from a CD34+ HSPC. This cell is therefore characterized in that it expresses the CD7 marker, which is known to be one of the earliest markers during the lymphopoiesis of the T cells. Depending on the state of differentiation in the T lymphoid pathway, it can express or not the CD34 marker (loss of CD34 during differentiation). Such T cell progenitor may also express or not the CD5 marker.
  • T-cell progenitors are those cells which can be found in the post-natal thymus, i.e. early thymic progenitor (ETP) (CD34+/CD45RA+/CD7+), proT1 cells (CD34+CD45RA+CD7++CD5 ⁇ CD1a ⁇ ), proT2 cells (CD34+CD45RA+CD7++CD5+CD1a ⁇ ) and preT cells (CD34 ⁇ CD7++/CD5+CD1a+).
  • ETP early thymic progenitor
  • TCP T-cell receptor loci rearrange in a highly ordered way (TCR ⁇ -TCR ⁇ -TCR ⁇ -TCR ⁇ ).
  • T-cell progenitors are well known in the state of the art. They are cited in particular by Reimann et al (STEM CELLS 2012; 30:1771-1780.) and by Awong et al (2009, op.cit.).
  • RGDS peptide is intended to designate any peptide or protein that contains the RGDS pattern, so that it can bind integrin VLA-5. Such peptide or protein can be tested for its ability to bind VLA-5 integrin by methods known and reported in the art. RGDS peptide binds to integrin VLA-5 (Very Late Antigen-5), which is a dimer composed of CD49e (alpha5) and CD29 (beta1).
  • Presence of such a heparin-binding domain is particularly favorable when the CD34+ cells are exposed to a viral (especially a retroviral) vector in order to transduce them and obtain T cell progenitors expressing a transgene.
  • a CS-1 peptide or CS-1 pattern is a 25 amino acids peptide (DELPQLVTLPHPNLHGPEILDVPST, SEQ ID NO: 6), described by Wayner et al, 1989, J. Cell Biol. 109: 1321).
  • This CS-1 pattern binds to the VLA-4 (Very Late Antigen-4) receptor.
  • This antigen is a dimer integrin, composed of CD49d (alpha 4) and CD29 (beta 1).
  • the fibronectin fragment is present in the culture medium or immobilized on the inner (in particular the bottom) wall of the container.
  • Fibronectin is a protein, which in its natural form is a v-shaped large dimer of 100 nm long and 460 kDa. The two monomers are connected by two disulfide bridges at their C-terminus.
  • the term “fibronectin” or “fibronectin fragment” is understood to mean the natural fibronectin protein (i.e. any isoform produced by alternative splicing), but also a monomer of this protein, or a fragment of this protein (but containing the peptide RGDS, as well as CS-1 peptide and heparin binding site).
  • Retronectin® A fibronectin which is particularly suitable for carrying out the process herein disclosed is Retronectin®.
  • This protein corresponds to a fragment of a human fibronectin (CH-296 fragment, Kimizuka et al., J Biochem., 1991 August 110 (2):284-91, Chono et al., J Biochem 2001 September 130 (3):331-4) and contains the three functional domains that are preferred for implementation of the method (the cell-binding C domain containing the RGDS peptide, the heparin-binding domain and the CS-1 sequence).
  • This protein is sold in particular by the company Takara Bio Inc. (Shiga, Japan).
  • the fibronectin fragment is immobilized (i.e. bound to a solid support and is not present free in solution (although it is possible that certain elements may be found in solution)).
  • This solid support is preferably the bottom wall of the container in which the process is carried out.
  • beads such as polymer or magnetic beads (with a diameter generally comprised between 1 and 5 ⁇ m).
  • the binding of the protein or peptide to these beads may or may not be covalent.
  • Methods for attaching a protein or peptide to the beads are known in the art. It is also possible to introduce the fibronectin fragment into a semisolid medium, such as agar or gel.
  • this immobilization may also be covalent or not.
  • this immobilization is carried out non-covalently by allowing the fibronectin fragment to be absorbed onto the glass or plastic composing the bottom wall of the container.
  • the differentiation of the CD34+ cells into T-cell progenitors is carried out together with the transduction or transfection (including NucleofectionTM, a specific electroporation system developed by Lonza) of the CD34+ cells by means of a vector (such as a viral vector or a nucleic acid fragment such as a plasmid or plasmidic RNA or DNA sequences) in order to introduce a gene of interest (or a system for gene editing) in these cells.
  • a vector such as a viral vector or a nucleic acid fragment such as a plasmid or plasmidic RNA or DNA sequences
  • the cells exposed to the Notch ligand and the fibronectin fragment, with TNF-alpha are also exposed to a viral supernatant for at least part of their time of exposure to the Notch ligand and fibronectin fragment, with TNF-alpha.
  • the CD34+ cells are exposed to a system making it possible to perform gene editing.
  • Such systems are now widely known and described in the art and are essentially based on nucleic acid double-break repair.
  • Such genome editing system may use a nuclease selected from the group consisting of meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), and CRISPR-Cas nucleases.
  • ZFNs zinc finger nucleases
  • TALEN transcription activator-like effector-based nucleases
  • CRISPR-Cas nucleases CRISPR-Cas nucleases.
  • the Notch ligand is the Delta-like-1 protein (SEQ ID NO: 1) or a fragment thereof (soluble domain).
  • the Notch ligand is the Delta-like-4 protein (SEQ ID NO: 2).
  • said Notch ligand is a fusion protein comprising the soluble domain of a natural Notch ligand fused to an Fc region of an IgG protein.
  • the soluble domain of a Notch ligand represents the extracellular portion of said ligand.
  • Varnum-Finney et al J Cell Sci., 2000 December; 113 Pt 23:4313-8
  • Varnum-Finney et al described a fusion protein of the soluble part of DL-1 with an Fc portion of IGg1.
  • Reimann et al (op cit) described a fusion protein of the soluble part of DL-4 (amino acids 1-526) with the Fc fragment of an IgG2b immunoglobulin.
  • the IgG protein is an IgG2.
  • the sequence of the Notch ligand used in the method herein disclosed is SEQ ID NO: 7.
  • a commercially available product comprising the extracellular domain (Met 1-Pro 524) of human DLL4 (full-length DLL4 accession number NP_061947.1) fused to the Fc region of human IgG 1 at the C-terminus is a DL4 protein is also suitable for use herein.
  • the culture medium used in the context of the method herein disclosed is any medium adapted for culturing CD34+ cells and T cells. Mention may in particular be made of ⁇ -MEM, DMEM, RPMI 1640, IMDM, BME, McCoy's 5A, StemSpanTM, in particular SFII (StemCell Technologies) media or Fischer's medium.
  • StemSpanTM SFII medium contains, in particular, Iscove's MDM, Bovine serum albumin, Recombinant human insulin, Human transferrin (iron-saturated), 2-Mercaptoethanol.
  • a suitable and preferred culture medium for carrying out the process herein disclosed is the X-VIVOTM medium (Lonza, Basel, Switzerland). This medium was used in particular by Jonuleit et al (Eur J Immunol, 1997, 27, 12, 3135-42) and Heil et al (J Immunol, 1998, 161, 4, 1947-53).
  • a basal medium is used (i.e., which a medium that allows the growth of the cells without the need to add supplements), in which, however, one preferably would add serum, and/or growth factors and cytokines.
  • fetal bovine serum (FBS) or fetal calf serum (FCS), autologous human serum or human AB serum is preferably added to the basal culture medium.
  • this medium is supplemented with at least 15% of fetal serum, more preferably at least 20%.
  • the FBS is particularly suitable for the implementation of the process.
  • the defined FBS is a high-quality serum which has been analyzed and filtered to avoid the presence of viral particles. It is sold as such by many suppliers, such as the HyCloneTM Defined Fetal Bovine Serum (FBS) of Thermo ScientificTM.
  • the culture medium is also preferably complemented with cytokines and growth factors.
  • cytokines and growth factors are especially selected from the group consisting of SCF (stem cell factor), thrombopoietin (TPO, also called megakaryocyte growth and development factor, MGDF), Flt3-Ligand (which is a growth factor Hematopoietic), interleukin 3 (IL-3), interleukin 7 (IL-7) and SCF (stem cell factor).
  • TPO thrombopoietin
  • MGDF megakaryocyte growth and development factor
  • Flt3-Ligand which is a growth factor Hematopoietic
  • IL-3 interleukin 3
  • IL-7 interleukin 7
  • SCF stem cell factor
  • the culture medium contains at least three, preferably at least four of these cytokines or growth factors, in addition to TNF-alpha.
  • cytokines are added.
  • these three cytokines are Interleukin-7 (IL-7), SCF (Stem Cell Factor) and Flt-3 Ligand (hematopoietic growth factor).
  • cytokines i.e. the three cytokines mentioned above and TPO (thrombopoietin) are added.
  • the nature of the cytokines and growth factors can be varied during the implementation of the method.
  • IL-3, IL-7, SCF, TPO, and Flt3-L can be used in the medium if the step of pre-activating the cells prior to addition of the viral vector, and then supplement the medium only with IL-7, SCF, TPO, and Flt3-L after the vector is removed.
  • cytokine and growth factor mixtures are sufficient to induce the differentiation of CD34+ cells into T-cell precursors and generally the culture medium comprises no other cytokine or growth factor, except TNF-alpha, which, as described in the examples, makes it possible to increase the number of T cell precursors.
  • the total duration of exposure of the CD34+ cells in the presence of the Notch ligand, of the protein or peptide exhibiting the RGDS motif and of TNF-alpha is generally carried out for a time preferably of more than 3 days and less than 10 days.
  • This exposure may vary depending on whether the cells are transduced. Thus, an exposure time of three days may be sufficient for adult stem cells not transduced, whereas it will generally be longer for infantile stem cells (about 7 days) or when transduction is performed.
  • CD34+ cells are obtained from a bone marrow puncture, from umbilical cord blood or from peripheral blood from adult donors, which have been mobilized particularly with G-CSF or any other mobilizing agent known in the art. Methods for sorting CD34+ cells are known in the art. In particular, magnetic beads having an antibody recognizing CD34 on their surface can be used for this purpose.
  • the cell culture vessel is prepared by immobilizing the Notch ligand and the fibronectin fragment on the inner (preferably the lower) surface prior to exposing the CD34+ cells.
  • Retronectin® or other fibronectin naturally adhere to the plastic of the cell culture box (Petri dish or 24-well box, or other).
  • Notch ligand is used as a fusion protein with the Fc fragment of an immunoglobulin, this Fc fragment also adheres to the plastics. It is therefore sufficient to leave the container in the presence of these compounds for a few hours in order to obtain the appropriate coating.
  • a method to coat such culture container with the Notch ligand and the fibronectin fragment is disclosed in details in WO 2016/055396 and can be applied for implementing the method as herein disclosed.
  • a concentration of 25 ⁇ g/ml is particularly adapted (especially when Retronectin® is used), although one can use other concentrations (higher or lower).
  • CD34+ cells are added at a concentration comprised between 10 6 et 10 7 cells/ml, in particular around 2 ⁇ 10 6 CD34+ cells/ml in the culture vessel.
  • a plate of between 2 to 10 cm 2 i.e. a plate from 24 to 6 wells.
  • a plate from 24 to 6 wells.
  • a 6 well plate one will add between 8 ⁇ 10 4 and 2 ⁇ 10 6 cells per well.
  • the quantity of cells to add is adapted by the person skilled in the art, according to the container used.
  • the cells are placed in the well, in the selected basal medium, supplemented with TNF-alpha, and preferentially supplemented with growth factors and cytokines, as indicated above.
  • the concentrations of cytokines or growth factors are between 2 and 300 ng/ml.
  • the concentration is higher than 40 ng/I and lower than 300 ng/ml or 200 ng/I, more preferably around 100 ng/ml.
  • SCF and Flt3-L can be used at des concentrations in the range of 300 ng/ml, TPO and IL-7 in the range of 100 ng/ml, and IL-3 at about 40 ng/ml.
  • TNF-alpha is preferably used at a concentration equal or higher than 5 ng/ml. Indeed, as demonstrated in the examples, this low concentration is enough to obtain the proliferation of the T cell precursors, without modifying the differentiation pathway.
  • the TNF-alpha concentration can be as high as 300 ng/ml or 200 ng/ml.
  • An appropriate concentration is around 100 ng/ml.
  • other concentrations such as 10 ng/ml, 20 ng/ml or 50 ng/ml are also suitable.
  • the invention thus relates to an in vitro method for generating T cells precursors comprising the step of culturing CD34+ cells in a suitable medium comprising TNF-alpha and in the presence of an immobilized Notch ligand, and optionally the fibronectin fragment as disclosed above.
  • the invention thus relates to an in vitro method for expanding T cells precursors comprising the step of culturing CD34+ cells in a suitable medium comprising TNF-alpha and in the presence of an immobilized Notch ligand, and optionally the fibronectin fragment as disclosed above.
  • Expanding the T cells precursors is intended to mean that there are more T cell precursors than when the TNF-alpha is not used, and/or that there are more T cell precursors than the number of CD34+ cells introduced in the container.
  • the T cells precursors obtained by the above methods are CD34 ⁇ /CD7+/CD5 ⁇ precursors.
  • the cells don't harbor the CD1a marker either.
  • the T cells precursors obtained by the above methods are CD34 ⁇ /CD7+/CD1a ⁇ precursors.
  • the population of T cell precursors obtained by the present method express the CD7 marker, and that more than 80% of the cells expressing this marker have the above phenotype (not expressing
  • This phenotype is generally obtained after 7 days of culture.
  • the CD34+ cells are preferably not cord blood cells.
  • the method may also be used with and is applicable to cord blood CD34+ cells, and it also leads to improved results.
  • the method is particularly interesting when implemented with CD34+ cells that have been isolated from an adult patient.
  • Said patient may be a healthy donor, or a donor with a disease, and particularly for which the cells will be corrected by viral transduction.
  • the cells may be cultured for more than 3 days, and preferably for at least 5 days, more preferably for at least or exactly 6 days, most preferably for at least or exactly 7 days, although the duration of culture may last longer.
  • TNF-alpha is preferably added to the culture medium from day 0 (i.e. at the beginning of CD34+ cells culture) and shall remain present, in the culture medium, for at least three days, and preferably during all the time the cells are culture (i.e. preferably about 7 days).
  • StemRegenin 1 4-(2-(2-(Benzo[b]thiophen-3-yl)-9-isopropyl-9H-purin-6-ylamino)ethyl)phenol, CAS 1227633-49-10) in the culture medium already containing the TNF-alpha.
  • the invention also relates to a method for obtaining T cells progenitors, comprising the steps of
  • Purification may be performed by washing the cells and resuspending such in a basal medium.
  • This method may also comprise the step of conditioning the T cells progenitors in a pouch for injection to a patient.
  • these cells are reconditioned in a saline solution containing 5% HSA such as AlbunormTM 5% 50 g/L (Octopharma, Lingolsheim, France).
  • These cells may also be frozen according to methods known in the art.
  • the invention also relates to a pouch for intravenous injection, containing a population of T cells progenitors (susceptible to be obtained or as obtained by a method as described above), among which the proportion of CD7+ cells in this population is higher than 80%, more preferably higher than 85%.
  • the invention also relates to a pouch for intravenous injection, containing a population of CD7+ T cells progenitors (susceptible to be obtained or as obtained by a method as described above), where the proportion of CD34 ⁇ and CD5 ⁇ cells (cells that are CD7+ and both CD34 ⁇ and CD5 ⁇ ) in this population is higher than 80%, more preferably higher than 85%.
  • the invention also relates to a pouch for intravenous injection, containing a population of CD7+ T cells progenitors (susceptible to be obtained or as obtained by a method as described above), where the proportion of CD34 ⁇ cells (cells that are CD7+ and CD34 ⁇ ) in this population is higher than 50%, more preferably higher than 60%. Furthermore, at least 80%, and more preferably at least 85% of the cells in this population are CD1a ⁇ cells.
  • the invention also relates to an in vitro method for obtaining transformed T-cells progenitors, comprising the steps of
  • transformed T-cells progenitors expressing a transgene, integrated within their genome
  • the invention also relates to an in vitro method for obtaining modified T-cells progenitors, comprising the steps of
  • T cells progenitors modified by gene editing are obtained, after potential steps of washing and culturing.
  • the invention also relates to T cells progenitors, in particular as obtained by the method herein disclosed, for their use in an immunosuppressed patient, in particular for allowing immune reconstitution in this patient and/or obtaining an immune protection against infections in said patient, during a period of some months (at least two months, preferably at least six months).
  • the patient is an immunosuppressed patient.
  • the reasons for the deficiency may be multiple: hereditary immune deficiency, chemotherapy for leukemia, conditioning, graft containing only stem cells, post-graft treatment for prophylaxis of GVH (graft-versus-host disease), age of patient, and complications such as infections.
  • the patient can be immunosuppressed due to the depletion of its immune cells following therapy before hematopoietic stem cells transplantation.
  • the graft may be an allograft (in this case, the T cell progenitors are preferably derived from a partially HLA-compatible donor), or an autograft (in which case the T cell progenitors have preferentially being transformed by a vector in order to express a gene and/or a protein making it possible to correct a genetic defect in said patient).
  • the T cell progenitors are preferably a population of CD7+ cells (i.e. a population where at least 75%, more preferably at least 80% of cells in the population express the CD7 marker).
  • This population is also part of the invention. In particular, it is susceptible to be obtained by a method herein disclosed. In a specific embodiment, it is obtained by a method herein disclosed.
  • the T cell progenitors are preferably a population of CD7+ cells (i.e. a population where at least 75%, more preferably at least 80% of cells in the population express the CD7 marker) where the proportion of CD34 ⁇ and CD5 ⁇ cells (cells that are CD7+ and both CD34 ⁇ and CD5 ⁇ ) in this population is higher than 80%, more preferably higher than 85%.
  • This population is also part of the invention. In particular, it is susceptible to be obtained by a method herein disclosed. In a specific embodiment, it is obtained by a method herein disclosed.
  • the T cell progenitors are preferably a population of CD7+ cells (i.e. a population where at least 75%, more preferably at least 80% of cells in the population express the CD7 marker). In this population, more than 50%, more preferably more than 60% of cells don't express the CD34 marker. In this population at least 80%, more preferably at least 85% of cells don't express the CD1a marker.
  • the proportion of CD7+ CD1a ⁇ cells in this population is preferably at least 80%.
  • This population is also part of the invention. In particular, it is susceptible to be obtained by a method herein disclosed. In a specific embodiment, it is obtained by a method herein disclosed.
  • a cell is positive or not to a surface marker (CD7, CD34, CD5 or CD1a)
  • a surface marker CD7, CD34, CD5 or CD1a
  • flow cytometry after the cells have been marked with fluorescent antibodies directed against the surface antigen. The principle is that a signal will be emitted, for each cell of the population, with a given intensity, and cells are considered as positive for the antigen if the signal is higher than a given threshold.
  • CD34 a control population consisting of a population of HPSC (such as one isolated from cord blood or from mobilized peripheral blood) is used to determine the appropriate thresholds. In this population of cells, the cells are CD34+ CD7 ⁇ CD5 ⁇ , or CD34+ CD7 ⁇ CD1a ⁇ . With this control, it is possible to determine threshold for each antigen that will be used to determine whether cells in another population are positive or not for these antigens.
  • the control population generally will contain around 90% of CD34+ CD7 ⁇ CD5 ⁇ , or of CD34+ CD7 ⁇ CD1a ⁇ hematopoietic stem cells.
  • the threshold is the signal intensity level for which the cells of the population can be sorted in a 90/10 proportion.
  • CD7 a control population is used, obtained by isolation of Peripheral Blood Mononuclear Cell (PBMC) by any technique known in the art, and in particular a density gradient technique such as Ficoll-Paque PLUS (GE Healthcare Life Sciences).
  • PBMC Peripheral Blood Mononuclear Cell
  • CD7 (resp. CD5 or CD1a) positive cells are isolated using any technique known in the art such as the MACS® technique (Magnetic Cell Isolation and Cell Separation, Miltenyi Biotec) which uses magnetic beads with anti-CD7 (resp. anti.CD5 or anti-CD1a) antibody.
  • MACS® technique Magnetic Cell Isolation and Cell Separation, Miltenyi Biotec
  • the cells will essentially be CD7+ (resp. CD5+ or CD1a+), it is believed that the proportion would be around 90/10.
  • the thresholds for assessing whether a cell is positive to a surface antigen are determined using the control population for this antigen, and would be the intensity for which more than 90% of the cells of the control population have a higher signal intensity.
  • a cell is considered as being positive for an antigen if the intensity signal for this antigen is higher than the threshold as determined above, and negative for the antigen if the intensity signal for this antigen is lower than the threshold as determined above.
  • CD1a marker may prove to be favorable, as cells expressing this CD1a marker may not be very efficient to reach the thymus and may thus be as efficient as CD1a ⁇ cells for in vivo repopulation. Since the reconstitution potential of CD1a+ cells is uncertain, it is thus preferable to lower the amount of such cells in the population.
  • the invention also relates to a method for treating an immunosuppressed patient, in particular for the purpose of allowing an immune reconstitution, at least temporarily, in this patient, comprising the step of administering to said patient T-cell progenitors, as described above.
  • This method may also include the step of obtaining such progenitors by exposing CD34+ cells to a Notch ligand in the presence of TNF-alpha (as described above) and preferably to a protein or peptide having the RGDS motif and/or the CS1 motif, in particular A fibronectin fragment as described above, under the conditions mentioned above.
  • a Notch ligand in the presence of TNF-alpha (as described above) and preferably to a protein or peptide having the RGDS motif and/or the CS1 motif, in particular A fibronectin fragment as described above, under the conditions mentioned above.
  • a therapeutically effective amount is administered, that is to say of the order of 1 to 5 ⁇ 10 6 of progenitors per kg, which makes it possible to provide the patient with cells capable of playing a protective role with regard to infections during a few months (of the order of about 6 months).
  • this administration of T cell progenitors is performed just prior to, just after or concomitantly with a hematopoietic stem cell transplant in said patient.
  • the injected cells can be transformed by a vector intended to allow the correction of a genetic defect in said patient.
  • the T cell progenitors are injected to a patient that doesn't need a hematopoietic stem cell transplant. Indeed, it is possible to use the transformed or transduced T cells progenitors to treat some immunodeficiencies, in which only T cells are affected, HIV or cancer patients (using the progenitors modified to lead to CAR-T cells), without the need to perform the immune system depletive chemotherapy.
  • TNF-alpha purine derivative StemRegenin 1 (SR1, disclosed in Boitano et al, Science. 2010 Sep. 10; 329(5997):1345-8).
  • SR1 can be substituted to TNF-alpha (i.e. used in place of TNF-alpha) to obtain T cell progenitors from CD34+ cells, with a beginning of differentiation, and expansion of the cells (increase in the number of cells).
  • the concentration of SR1 is preferably in the range of 750 nM (30 ng/ml), also higher concentration such as 1500 nM or 2500 nM (100 ng/ml), or even 5000 nM (200 ng/ml) or lower such as 500 nM (20 ng/ml) can also be envisaged.
  • concentrations When used alone, but particularly in combination with TNF-alpha, much lower concentrations can be used, as low as 3 ng/ml, or 10 ng/ml.
  • Suitable concentrations also include 30 ng/ml or 100 ng/ml. Consequently, any concentration higher than 3 ng/ml, or higher than 10 ng/ml is suitable to increase the differentiation of the CD34+ cells to T-cells progenitors.
  • SR1 is a ligand (an antagonist) of the Aryl hydrocarbon/Dioxin receptor (AhR).
  • AhR antagonists can be used alone, or in combination with TNF-alpha, to promote differentiation of CD34+ cells into the T-cell progenitor lineage.
  • the amount of AhR antagonist is to be determined on a case-by-case basis by one of skill in the art, taking into consideration the IC50 of the antagonist (SR1 has an IC50 of 127 nM, whereas CH 223191 has an IC50 of 30 nM) and the fact that some products may have an agonist activity towards the AhR when used at high concentrations (such as alpha-naphthoflavone) or depending of the cellular context (such as omeprazole).
  • IC50 of the antagonist SR1 has an IC50 of 127 nM
  • CH 223191 has an IC50 of 30 nM
  • some products may have an agonist activity towards the AhR when used at high concentrations (such as alpha-naphthoflavone) or depending of the cellular context (such as omeprazole).
  • an effective concentration of CH 223191 would be well below the effective concentration of SR1, herein disclosed.
  • the invention also relates to
  • the invention also relates to a kit for performing any method as indicated above, comprising:
  • the invention in another embodiment, relates to a kit comprising the same elements (i) and (ii) as indicated above, and a progenitor expansion medium (iii) which contains an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular SR1, and preferably three cytokines, in particular selected from SCF, TPO, Flt3L, and IL-7. It is preferred when the progenitor expansion medium contains SR1 and all four cytokines SCF, TPO, Flt3L, and IL-7.
  • the progenitor expansion medium (iii) contains TNF-alpha and an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular SR1, and preferably three cytokines, in particular selected from SCF, TPO, Flt3L, and IL-7. It is preferred when the progenitor expansion medium contains TNF-alpha, SR1 and all four cytokines SCF, TPO, Flt3L, and IL-7.
  • kit is particularly adapted and designed for performing the methods herein disclosed.
  • the coating medium (i) is first used to coat the walls of a culture vessel.
  • the medium (ii) is then used to culture CD34+ cells (either obtained from cord blood or from mobilized peripheral blood, in particular from an adult).
  • Such medium is generally and preferably used at a 1 ⁇ concentration (i.e. it can be used without dilution).
  • the medium (iii) is generally presented as a 10 ⁇ dilution (i.e. it has to be diluted in a medium (ii) for use.
  • the reconstituted medium from media (ii) and (iii) is then used to promoter differentiation of the CD34+ cells to T-cell progenitors, in the T-cell lineage, as disclosed above.
  • the invention also relates to a method for increasing the number of T cells in a subject in need thereof, the method comprising administering to the subject an effective number of progenitor T cells as obtained by a method disclosed herein.
  • the invention also relates to progenitor T cells as obtained by any method herein disclosed for their use for treating a subject in need of an increased number of T cells.
  • the subject is a human.
  • the administered progenitor T cells are autologous. In another embodiment, the administered progenitor T cells are allogeneic.
  • the subject in need of the increased number of T cells has a medical condition causing or resulting in lymphopenia, in particular cancer, HIV infection, partial thymectomy, autoimmune disease, and/or organ transplant.
  • FIG. 1 Total nucleated cells number obtained starting with 20000 CD34+ cells from cord blood (CB, FIG. 1 .A) or mobilized peripheral blood (mPB, FIG. 1 .B), after 3 days (black bars) and 7 days (cumulative black and grey bars) of culture.
  • NC not complemented
  • SR1 addition of StemRegenin 1 (750 nM)
  • TNF-alpha addition of TNF-alpha (100 ng/ml)
  • FIG. 2 Number of CD7+ T-cell precursors obtained at day 7 starting with 20000 CD34+ cells from cord blood (CB, FIG. 2 .A) or mobilized peripheral blood (mPB, FIG. 2 .B). Black bars: CD34+CD7+ cells; grey bars: CD34-CD7+ cells.
  • FIG. 3 Expression of Bcl11b was analyzed on lived cells after 7 days of culture obtained starting with CD34+ cells from cord blood (CB) or mobilized peripheral blood (mPB) cultured in the presence (grey bars) or absence (black bars) of TNF-alpha.
  • FIG. 4 Combined effect of TNF-alpha and the Notch ligand DL4 on the number of CD7+ cells obtained at day 7 starting from CD34+ cord blood cells (CB, black bars, left) or mobilized peripheral blood (mPB, grey bars, right). (+/ ⁇ means presence or absence of DL4 or TNF-alpha).
  • FIG. 5 Frequency of myeloid cells at day 7 obtained starting from CD34+ cells from cord blood (CB) or mobilized peripheral blood (mPB) in presence (grey bars) or not (black bars) of TNF-alpha (Mean ⁇ SEM).
  • FIG. 6 Total CD7+ cells number obtained from day 3 to day 7 in a dose response assay of TNF-alpha, starting with CD34+ cells from cord blood (CB, FIG. 6 .A) or mobilized peripheral blood (mPB, FIG. 6 .B).
  • CD34+ cells from cord blood (CB, FIG. 6 .A) or mobilized peripheral blood (mPB, FIG. 6 .B).
  • FIG. 7 Proportion of CD34 ⁇ CD7+ cells (grey bars) vs CD34+CD7+ cells (black bars) in a dose response assay of TNF-alpha starting with CD34+ cells from cord blood (CB, FIG. 7 .A) or mobilized peripheral blood (mPB, FIG. 7 .B)
  • FIG. 8 Proportion of cells in the different phases of the cellular cycle.
  • A. CB cells differentiated from cord blood; B. cells differentiated from mobilized peripheral blood cells. NC: non complemented; TNF-alpha: cultured in presence of TNF-alpha (20 ng/ml); SR1: cultures in presence of SR1 (30 ng/ml)
  • FIG. 9 percentage (A) and total number (B) of CD5+CD7+ cells cultured starting with CD34+ cells from cord blood in presence of TNF-alpha and/or SR1 at various concentrations, after 7 days of culture.
  • mPB samples were collected from healthy donors after G-CSF mobilization. Samples were directly enriched for CD34+ cells. The informed consent was given by each donor (Biotherapy Department, Necker Hospital, Paris).
  • CD34+ cells from human CB or mobilized peripheral blood samples were cultured in 24-well plates or 6-well plates that had been coated with recombinant human fibronection (RetroNectin®, Clontech/Takara) and DL-4 (5 ⁇ g/ml, PX′Therapeutics, Grenoble, France). Coating was performed for 2 h at 37° C., DL-4 coated wells were then blocked with bovine serum albumin 2% (BSA) in phosphate-buffered saline (PBS) for 30 minutes at 37° C. and washed with PBS.
  • BSA bovine serum albumin 2%
  • PBS phosphate-buffered saline
  • T-lymphoid potential of native CD34+ CB cells and TNF- ⁇ induced T cell progenitors generated by exposure to DL-4 was assessed in OP9/DL-1 co-cultures, as previously described (Six et al, Blood Cells Mol Dis. 2011 Jun. 15; 47(1):72-8 and Six J Exp Med. 2007 Dec. 24; 204(13):3085-93).
  • CD7+ cells were sorted on Ariall after 7 days of culture. Total RNA of sorted cell fractions from day 3 and day 7 was isolated with the Rneasy Micro Kit (Qiagen, Courtaboeuf, France). RT2 Profiler PCR arrays were performed following the protocol detailed in the RT2 Profiler PCR Array Handbook (SA Biosciences, Frederick Md.).
  • Monoclonal antibodies against human CD34 (AC136), CD3 (BW264/56), CD45 (5B1) were purchased from Miltenyi Biotech (Bergisch Gladbach, Germany), and CD4 (SK4), CD7 (M-T701), CD25 (M-A251), 7-aminoactinomycin D (7AAD) were from BD Biosciences (San Jose, Calif.).
  • Anti-human CD8 (RPAT8) was from Sony Biotechnology (San Jose, USA).
  • the Anti-human Ctip2 (Bcl11b) antibody was from Abcam (Cambridge, UK).
  • CD34+ cells from CB and mPB were labeled using the CellTraceTM CFSE kit (Life Technologies, Carlsbad, Calif.) prior to culture with DL-4 and TNF-alpha (Life Technologies). The cells' staining intensity was measured prior to culture each day from day 3 to day 7. CFSE-positive cell were analyzed on a Gallios cytometer (Beckman Coulter).
  • mice obtained from the Jackson Laboratory, Bar Harbor, Me., http://www.jax.org
  • mice obtained from the Jackson Laboratory, Bar Harbor, Me., http://www.jax.org
  • Progeny derived from mPB CD34+ HSPCs in 7-day DL-4 cultures with or without TNF ⁇ (3 ⁇ 10 5 or 1 ⁇ 10 6 ) were injected intra-hepatically into NSG neonates (0-4 days old).
  • Control mice were injected with either 3 ⁇ 10 5 non-cultured mPB CD34+ cells or 100 ul PBS.
  • Average engraftment levels of NSG mice were determined from 4 to 12 weeks post-transplant. Flow cytometry analysis was performed on freshly cells collected from femur, thymus, peripheral blood and spleen. Cells were treated with 1 ⁇ red blood cell lysis buffer (Biolegend, US) and washed before stained by antibodies.
  • TCR gene rearrangement analysis was performed in duplicate and on the two independently purified subsets (average is shown).
  • TCR- ⁇ quantification (D ⁇ 2-D ⁇ 3, D ⁇ 2-J ⁇ 1, and D ⁇ 3-J ⁇ 1) was performed with the listed sets of primers and probes.
  • D ⁇ 2 (SEQ ID No 9) 5′-CAAGGAAAGGGAAAAAGGAAGAA-3′; D ⁇ 3, (SEQ ID No 10) 5′-TTGCCCCTGCAGTTTTTGTAC-3′; and D′3 probe, (SEQ ID No 11) 5′-ATACGCACAGTGCTACAAAACCTACAGAGACCT-3′.
  • TCR rearrangements by multiplex fluorescent PCR was performed by separation of fluorochrome-labeled single stand PCR products in a capillary sequencing polymer and detected via automated laser scanning.
  • Cells were washed by cold PBS and resuspended in binding buffer at a concentration of 1 million cells/ml. After adding 5 ul Annexin V-PE (BD Bioscience) and 2 ul 7AAD, cells were incubated in the dark at room temperature for 15 min. Subsequently, cells were washed with 500 ul binding buffer and resuspended in 100 ul binding buffer to be analyzed within 1 hour.
  • Annexin V-PE BD Bioscience
  • 7AAD 2 ul 7AAD
  • FIG. 1 shows that addition of TNF-alpha to the cell culture medium makes it possible to multiply the total number of cells recovered at day 7 by 10 times as compared to culture without TNF-alpha, either when starting with CD34+ cells issued from cord blood ( FIG. 1 .A) or from PB ( FIG. 1 .B).
  • FIG. 2 shows that addition of TNF-alpha to the cell culture medium makes it possible to multiply the number of CD7+ cells in by 20 to 40 times, either when starting with CD34+ cells issued from cord blood ( FIG. 2 .A) or from PB ( FIG. 2 .B).
  • the improvement is especially high for the CD34-CD7+ cell population.
  • the surface markers present at the surface of the cells obtained after 7 days of culture were determined by flow cytometry.
  • HSPCs differentiate into CD34 ⁇ CD7+CD5 ⁇ T-cell precursors.
  • the surface markers present at the surface of the cells obtained after 10 days of culture were also determined by flow cytometry.
  • DL-4 T-cell precursors do not exhibit any signs of TCR rearrangement with or without TNF-alpha or SR1 after 7 days of culture (data not shown).
  • Bcl11b is an important transcriptional factor uniquely switched on since T-cell commitment and absolutely required for T-cell differentiation.
  • FIG. 3 shows that TNF-alpha increases the proportion of total cells expressing Bcl11b transcription factor. When cultured with TNF-alpha, the proportion of Bcl11b expressing cells was increased.
  • FIG. 5 shows that the culture in the presence of TNF-alpha made such cells not detectable, whereas their proportion is less than 22% when CD34+ cells are cultured without TNF-alpha.
  • Apoptosis markers (7AAD and Annexin5) were studied.
  • TNF-alpha Various doses of TNF-alpha were used.
  • FIG. 6 shows that TNFa may increase CD7+ cell numbers during culture, when the concentration is more than 10 ng/ml, either for CB cells ( FIG. 6 .A) or mPB cells ( FIG. 6 .B).
  • TNF-alpha increases the T-cell differentiation after only 4 days of culture in DL-4. There was no difference between the concentration 10, 50 and 100 ng/ml (not shown).
  • TNF-alpha The effect of TNF-alpha on CB and mPB on T-cell differentiation (percentage of CD34 ⁇ CD7+ cells) was found to be concentration-dependent at low concentration ( FIG. 7 ).
  • the total number of CD7+ T-cell precursors was not different from 5 ng/ml to 100 ng/ml.
  • TNF-alpha was found to increase the proliferation of CD34+CD7+ T-cell precursors since day 3 in DL-4 culture as compared to culture conditions without TNF-alpha (data not shown).
  • FIG. 4 shows that without DL4, both CB and mPB failed to differentiate into CD7+ T-cell precursors. Even the complementation of the medium with TNF-alpha could't rescue it.
  • CD34+CD7 ⁇ , CD34+CD7+ and CD34-CD7+ subsets were sorted, stained with CFSE (Carboxyfluorescein succinimidyl ester) and the dilution of CFSE (surrogate marker of cell proliferation) was followed from day 8 to 10.
  • CFSE Carboxyfluorescein succinimidyl ester
  • CD34+CD7+ and CD34 ⁇ CD7+ cells show increased proliferation when cultured with TNF-alpha. (Data not shown)
  • SR1 accelerates T-cell differentiation as shown by the presence of CD5+CD7+ cells at day 7.
  • the number of CD5+CD7+ cells is increased by the presence of both TNF-alpha and SR1 ( FIG. 9 ).
  • T-cell precursors induced in presence of TNF-alpha may largely fasten the reconstitution of the T-lineage in vivo.
  • recipient mice injected with mPB T-cell precursors produced in the presence of TNF-alpha have larger thymus than mice injected with mPB T-cell precursors produced without TNF-alpha.
  • T-cell precursors induced in presence of TNF-alpha can differentiate to activated TCR ⁇ T cells within 4 weeks in vivo.
  • TNF-alpha from day 0 in the DL-4 culture system leads to an increase of T-cell progenitors (defined by the surface expression of CD7) of 40 fold for mPB HSPC and 20 fold for CB HSPC at day 7.
  • CD7+ T-cell progenitors generated from both CB and mPB were mostly CD34 ⁇ and were CD1a negative. Cells were also mostly CD5 negative.
  • Bcl11b which is important fine-turning molecular for T-commitment and further T-cell differentiation.
  • TNF-alpha decreases expression of apoptosis markers and increases cell proliferation during the culture. It also inhibits myeloid cell production.
  • TNF-alpha in the DL4 culture system increase to a huge extent the amounts of T-cell progenitors produced from both human adult and cord blood HSPC. It may thus overcome the difficulty to obtain large amounts of T-cell progenitors from adult HSPC. It may also decrease the number of starting HSPC required in future clinical trials and the quantity of GMP grade and other reagents required, thus decreasing the costs of production of these T-cell progenitors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
US16/485,488 2017-02-13 2018-02-12 Method for generating t cells progenitors Abandoned US20200046767A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305161.6 2017-02-13
EP17305161 2017-02-13
PCT/EP2018/053406 WO2018146297A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/053406 A-371-Of-International WO2018146297A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/010,208 Continuation US11426430B2 (en) 2017-02-13 2020-09-02 Method for generating T cells progenitors

Publications (1)

Publication Number Publication Date
US20200046767A1 true US20200046767A1 (en) 2020-02-13

Family

ID=58185453

Family Applications (5)

Application Number Title Priority Date Filing Date
US16/485,488 Abandoned US20200046767A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors
US17/010,208 Active US11426430B2 (en) 2017-02-13 2020-09-02 Method for generating T cells progenitors
US17/173,632 Active US11638723B2 (en) 2017-02-13 2021-02-11 Method for generating T cells progenitors
US17/173,668 Active US11642376B2 (en) 2017-02-13 2021-02-11 Method for generating T cell progenitors
US18/296,623 Pending US20230293586A1 (en) 2017-02-13 2023-04-06 Method for generating t cells progenitors

Family Applications After (4)

Application Number Title Priority Date Filing Date
US17/010,208 Active US11426430B2 (en) 2017-02-13 2020-09-02 Method for generating T cells progenitors
US17/173,632 Active US11638723B2 (en) 2017-02-13 2021-02-11 Method for generating T cells progenitors
US17/173,668 Active US11642376B2 (en) 2017-02-13 2021-02-11 Method for generating T cell progenitors
US18/296,623 Pending US20230293586A1 (en) 2017-02-13 2023-04-06 Method for generating t cells progenitors

Country Status (17)

Country Link
US (5) US20200046767A1 (enExample)
EP (2) EP3580330B1 (enExample)
JP (2) JP7164798B2 (enExample)
KR (1) KR102666158B1 (enExample)
CN (1) CN110506110B (enExample)
AU (1) AU2018217404B2 (enExample)
BR (1) BR112019016672A8 (enExample)
CA (1) CA3053294A1 (enExample)
DK (1) DK3580330T3 (enExample)
ES (1) ES2931530T3 (enExample)
HU (1) HUE060548T2 (enExample)
IL (1) IL268641B2 (enExample)
MA (1) MA47541A (enExample)
PL (1) PL3580330T3 (enExample)
PT (1) PT3580330T (enExample)
WO (1) WO2018146297A1 (enExample)
ZA (1) ZA201905470B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079082A1 (en) * 2021-11-04 2023-05-11 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268641B2 (en) * 2017-02-13 2024-10-01 Assist Publique Hopitaux Paris Aphp Method for generating t cells progenitors
US20200308540A1 (en) * 2017-09-29 2020-10-01 Regents Of The University Of Minnesota Methods of making, expanding, and using a human progenitor t cell
CN112041431A (zh) 2018-02-14 2020-12-04 桑尼布鲁克研究所 产生t细胞谱系细胞的方法
CA3109546A1 (en) * 2018-09-07 2020-03-12 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
US20220315895A1 (en) * 2019-05-01 2022-10-06 Transfusion Health, Llc Methods of making oligopotent and unipotent precursors
CA3144640A1 (en) * 2019-06-24 2020-12-30 Children's Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
CA3159629A1 (en) * 2019-11-14 2021-05-20 Peter William ZANDSTRA Media formulations and methods for producing progenitor t cells
US20230159891A1 (en) * 2020-03-31 2023-05-25 Kyoto University T cell progenitor production method
JP2023553313A (ja) 2020-11-30 2023-12-21 チョ ファーマ インコーポレイテッド 細胞を富化するための抗体
CA3213581A1 (en) * 2021-05-25 2022-12-01 Kai Ling LIANG Generating t cell precursors via agonizing tumor necrosis factor receptor 2
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
AU2024211048A1 (en) 2023-01-27 2025-08-07 Notch Therapeutics (Canada), Inc. Method for generating t cell lineage populations from stem/progenitor cells
WO2024175738A1 (en) * 2023-02-22 2024-08-29 Smart Immune Method for thymus regeneration
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180208895A1 (en) * 2014-10-06 2018-07-26 Assistance Publique - Hopitaux De Paris Method for generating t-cell progenitors
US11426430B2 (en) * 2017-02-13 2022-08-30 Assistance Publique—Hopitaux de Paris Method for generating T cells progenitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
JP2001525176A (ja) 1997-12-04 2001-12-11 デューク・ユニバーシティー Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
RU2535966C2 (ru) 2008-09-12 2014-12-20 Криопрашис Криобиоложия Лтда. Клеточная терапия ишемической ткани
US8772028B2 (en) * 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
WO2011068962A1 (en) 2009-12-03 2011-06-09 The University Of Utah Research Foundation Methods for generating t lymphocytes from hematopoietic stem cells
US20130095079A1 (en) 2010-04-09 2013-04-18 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
US9834755B2 (en) * 2011-12-08 2017-12-05 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2014110353A1 (en) 2013-01-11 2014-07-17 The Trustees Of The University Of Pennsylvania Notch ligand bound bicompatible substrates and their use in bone formation
EP3027755B1 (en) * 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
KR20160145802A (ko) 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
US10131876B2 (en) * 2014-04-24 2018-11-20 Miltenyi Biotec Gmbh Method for automated generation of genetically modified T cells
WO2016039933A1 (en) 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders
WO2016205680A1 (en) * 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
EP3440198A4 (en) 2016-04-08 2019-11-06 The Governing Council of the Universtiy of Toronto PROCESS FOR THE PRODUCTION OF PRE-TREATMENT T CELLS FROM TRUNK AND / OR PRECURSOR CELLS AND USE THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180208895A1 (en) * 2014-10-06 2018-07-26 Assistance Publique - Hopitaux De Paris Method for generating t-cell progenitors
US11426430B2 (en) * 2017-02-13 2022-08-30 Assistance Publique—Hopitaux de Paris Method for generating T cells progenitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Schiavinato et al. TNF-alpha and Notch signaling regulates the expression of HOXB4 and GATA3 during early T lymphopoiesis. In Vitro Cell. Dev. Biol. 52:920-934, (Year: 2016) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079082A1 (en) * 2021-11-04 2023-05-11 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells

Also Published As

Publication number Publication date
US11426430B2 (en) 2022-08-30
JP7164798B2 (ja) 2022-11-02
US20210169934A1 (en) 2021-06-10
HUE060548T2 (hu) 2023-03-28
US11638723B2 (en) 2023-05-02
ES2931530T3 (es) 2022-12-30
KR20190117550A (ko) 2019-10-16
JP2022185024A (ja) 2022-12-13
AU2018217404A1 (en) 2019-09-05
AU2018217404A2 (en) 2019-09-19
US20210169935A1 (en) 2021-06-10
MA47541A (fr) 2019-12-18
US20230293586A1 (en) 2023-09-21
CN110506110B (zh) 2024-09-06
IL268641B2 (en) 2024-10-01
KR102666158B1 (ko) 2024-05-16
IL268641A (en) 2019-10-31
RU2019125600A3 (enExample) 2021-11-03
CA3053294A1 (en) 2018-08-16
CN110506110A (zh) 2019-11-26
AU2018217404B2 (en) 2024-03-28
PT3580330T (pt) 2022-12-06
IL268641B1 (en) 2024-06-01
RU2019125600A (ru) 2021-03-15
US11642376B2 (en) 2023-05-09
JP2020513844A (ja) 2020-05-21
BR112019016672A2 (pt) 2020-04-14
PL3580330T3 (pl) 2023-01-16
EP3580330A1 (en) 2019-12-18
DK3580330T3 (da) 2022-12-05
ZA201905470B (en) 2024-12-18
BR112019016672A8 (pt) 2022-11-22
EP4067482A1 (en) 2022-10-05
WO2018146297A1 (en) 2018-08-16
EP3580330B1 (en) 2022-08-31
US20200390817A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
US11642376B2 (en) Method for generating T cell progenitors
Shankar et al. Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
US12071635B2 (en) Method for generating T-cell progenitors
Sadeqi Nezhad et al. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Shimasaki et al. Natural killer cell reprogramming with chimeric immune receptors
KR102534472B1 (ko) 케모카인 리셉터와 세포 접착 분자를 발현하는 cd3 음성 세포의 집단, 및 그 이용 그리고 그 제조 방법
US20250230411A1 (en) Method for producing regulatory t cells
Netsrithong et al. Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells
Kremer et al. Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors
HK40081656A (en) Method for generating t cells progenitors
RU2797260C2 (ru) Способ получения предшественников т-клеток
HK40017982A (en) Method for generating t cells progenitors
HK40017982B (en) Method for generating t cells progenitors
WO2025220666A1 (en) Cytotoxic Lymphocytes Expressing Variable Region-Deleted T Cell Receptors
Birch et al. Biology of NK cells and NK cells in clinic
Shukla Controlled generation of progenitor T-Cells from hematopoietic stem cells and pluripotent stem cells
Guerrettaz Aging-associated changes in B-lymphopoiesis

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDRE, ISABELLE;CAVAZZANA, MARINA;MA, KUIYING;AND OTHERS;SIGNING DATES FROM 20190819 TO 20190903;REEL/FRAME:050850/0725

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDRE, ISABELLE;CAVAZZANA, MARINA;MA, KUIYING;AND OTHERS;SIGNING DATES FROM 20190819 TO 20190903;REEL/FRAME:050850/0725

Owner name: UNIVERSITE PARIS DESCARTES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDRE, ISABELLE;CAVAZZANA, MARINA;MA, KUIYING;AND OTHERS;SIGNING DATES FROM 20190819 TO 20190903;REEL/FRAME:050850/0725

Owner name: FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDRE, ISABELLE;CAVAZZANA, MARINA;MA, KUIYING;AND OTHERS;SIGNING DATES FROM 20190819 TO 20190903;REEL/FRAME:050850/0725

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: UNIVERSITE DE PARIS, FRANCE

Free format text: MERGER;ASSIGNOR:UNIVERSITE PARIS DESCARTES;REEL/FRAME:053289/0135

Effective date: 20200101

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: UNIVERSITE PARIS CITE, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:UNIVERSITE DE PARIS;REEL/FRAME:060530/0623

Effective date: 20220304

AS Assignment

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOHEILI, TAYEBEH-SHABI;DEVI MOIRANGTHEM, RANJITA;REEL/FRAME:060501/0971

Effective date: 20220704

Owner name: UNIVERSITE PARIS DESCARTES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOHEILI, TAYEBEH-SHABI;DEVI MOIRANGTHEM, RANJITA;REEL/FRAME:060501/0971

Effective date: 20220704

Owner name: FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOHEILI, TAYEBEH-SHABI;DEVI MOIRANGTHEM, RANJITA;REEL/FRAME:060501/0971

Effective date: 20220704

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOHEILI, TAYEBEH-SHABI;DEVI MOIRANGTHEM, RANJITA;REEL/FRAME:060501/0971

Effective date: 20220704

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION